Organizers claimed that nearly 2 million Hong Kong protesters took to the streets Sunday in a rally to demand the city's top official resign a day after she suspended — but...China Politicsread more
African swine fever, which has already ravaged pig herds in China and pushed up food prices there, could also drive up inflation in the other emerging markets, according to...Asia Economyread more
Consumer goods giant Unilever has taken the unusual step of having some of its marketing staff read their own DNA profiles to see whether finding out about their heritage has...Marketing.Media.Moneyread more
Stocks in Asia traded mixed on Monday as investors await a U.S. Federal Reserve meeting set to happen later in the week stateside.Asia Marketsread more
In the survey, 66% of Democratic primary voters say they'd be enthusiastic or comfortable about Biden as their nominee to take on President Trump in the 2020 election. Just...Politicsread more
Heavy rains caused unprecedented delays in planting this year and contributed to record floods across the central United States.Agricultureread more
Target's registers were down on Saturday for several hours preventing customers from checking out.Retailread more
Although Cook did not mention companies by name, his commencement speech in Silicon Valley's backyard mentioned data breaches, privacy violations, and even made reference to...Technologyread more
U.S. ambassador to Israel David Friedman called the gesture a "birthday present" to Trump, who turned 73 on Friday.Politicsread more
The outlook for Germany's economy and political stability are more uncertain than ever, writes Michael Ivanovitch.World Economyread more
The agreement, which is on the framework for the plan of adjustment, provide for more than a 60% average haircut for all $35 billion, a 36% haircut on pre-2012 general...Bondsread more
Gilead reported quarterly earnings and revenue on Tuesday that beat analysts' expectations, boosted by sales of its drugs in Japan.
The pharmaceutical company posted fourth-quarter earnings per share of $3.32, compared to $2.43 a share a year earlier. Revenue came in at $8.51 billion, up from $7.31 billion.
Analysts expected Gilead to report earnings of about $3 a share on $8.14 billion in revenue, according to a consensus estimate from Thomson Reuters.
Gilead's stock initially shot up 2 percent on the news, but pared gains after the company announced it approved a $12 billion share buyback and a 10 percent increase in the quarterly dividend.
Overall product sales increased across all geographies, the company said, especially in sales of its flagship hepatitis C treatments in Japan. Sales in that country also boosted HIV and liver disease treatment sales.
Fourth-quarter sales of hepatitis C treatment Harvoni declined year over year in the U.S. to $1.7 billion from $2 billion, but increased in Europe and abroad. Sovaldi saw a similar pattern in the U.S., falling to $660 million from $1.18 billion.
The Foster City, California-based company has been under fire as the entire biotechnology sector faces scrutiny over high drug prices.
Gilead boasts a market share of more than 90 percent of all hepatitis C treatments with its two highest-grossing products, Harvoni and Sovaldi, the company said on a conference call last year. A full course of Sovaldi currently goes for $84,000, and a 12-week Harvoni treatment costs $94,500.
The Massachusetts attorney general's office is the latest to lob allegations of unfair commercial conduct at Gilead, claiming in a letter last week the costs of Gilead's two leading hepatitis C drugs "may constitute an unfair trade practice in violation of Massachusetts law."
Gilead has said it is committed to expand access to its medicines, regardless of ability to pay. The company has said it offers a "support path" for those who may have trouble paying for its therapies.
"We agree with the Attorney General about the importance of helping all HCV patients — and that the advent of safe, effective regimens means we can now consider the possibility of eradicating the disease," a Gilead spokeswoman told CNBC, adding that the company had reached out to Healey about setting up a meeting to discuss the issue.
Gilead recently named a new CEO with John Milligan tapped to succeed John Martin, who is stepping down from the post but will assume the role of executive chairman.
Shares of Gilead are down more than 20 percent over the past year.
— CNBC's Everett Rosenfeld contributed to this article.